QuidelOrtho (NASDAQ:QDEL) shares tumbled 21.3% during afternoon trading today after the diagnostics company issued a grim full-year outlook, effectively overshadowing a second-quarter earnings beat.
Q2 Performance vs. Revised Annual Outlook
The company reported second-quarter revenue of $630.9 million and adjusted earnings per share (EPS) of $0.13, figures that successfully cleared Wall Street’s expectations. Despite this quarterly success, investors reacted sharply to the company’s decision to drastically lower its annual guidance.
QuidelOrtho now projects full-year revenue to land between $2.52 billion and $2.6 billion—a midpoint that sits 5.4% below prior analyst estimates. Furthermore, the company slashed its adjusted EPS guidance to a range of $0.65 to $0.90 per share, signaling to the market that internal headwinds are overshadowing recent operational gains.
Market Volatility and Investor Sentiment
This massive sell-off underscores a significant shift in market perception regarding the company’s near-term stability. While QuidelOrtho is no stranger to price swings—having recorded 51 moves greater than 5% over the past year—the severity of today’s decline highlights deep-seated investor concern over the company’s revised trajectory.
Contextualizing the Decline
The current turbulence follows a period of intense speculation regarding the company’s portfolio. Just one month ago, shares surged 34.7% amid reports that QuidelOrtho was exploring the sale of its point-of-care testing unit—the division behind its rapid COVID-19 antigen tests—for approximately $1.5 billion. Analysts have viewed a potential divestiture as a strategic move to alleviate the $3.8 billion debt burden inherited from the 2022 acquisition of Ortho Clinical Diagnostics.
Despite that brief rally, the broader trend for QuidelOrtho remains bearish. The stock has shed 56% of its value since the start of the year. Currently trading at $12.66 per share, the stock sits 64.2% below its 52-week high of $35.38 reached in January 2026. Long-term performance has been equally challenging, with a $1,000 investment made five years ago now valued at just $97.46.